TIGIT as an emerging immune checkpoint. PMID: 31828774
TIGIT in cancer immunotherapy. PMID: 32900861
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. PMID: 28258695
Tim-3, Lag-3, and TIGIT. PMID: 28900677
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. PMID: 27192565
TIGIT: a novel immunotherapy target moving from bench to bedside. PMID: 30232519
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. PMID: 25465800
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. PMID: 29915296
Targeting the "PVR-TIGIT axis" with immune checkpoint therapies. PMID: 32489646
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. PMID: 27620276
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. PMID: 27793572
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. PMID: 31234588
The relationship between TIGIT(+) regulatory T cells and autoimmune disease. PMID: 32172208
Immune checkpoint targeting TIGIT in hepatocellular carcinoma. PMID: 32774695
CD155T/TIGIT Signaling Regulates CD8(+) T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. PMID: 28883004
Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. PMID: 30733837
Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. PMID: 31485637
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. PMID: 25866972
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. PMID: 29986909
CD226(hi)CD8(+) T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. PMID: 32265229
CD155/TIGIT, a novel immune checkpoint in human cancers (Review). PMID: 33469677
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. PMID: 32275969
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma. PMID: 31387897
TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma. PMID: 32631956
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. PMID: 32591463
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. PMID: 30221069
Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. PMID: 32817209
TIGIT blockade improves anti-Mycobacterium tuberculosis immunity., PMID:40526725
Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human., PMID:40518289
SGSM1 as a pan-cancer biomarker: multi-omics insights into immune regulation, prognostic value, and therapeutic implications., PMID:40500484
Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs., PMID:40487483
Expression of PSMD14 in lung adenocarcinoma and its impact on immune cell infiltration and prognosis: a comprehensive analysis based on RNA and single-cell RNA sequencing., PMID:40475775
TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection., PMID:40475763
Impact of immune checkpoint TIGIT on the activation and function of natural killer cells in rheumatoid arthritis patients., PMID:40465407
Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy., PMID:40457441
TERT promoter methylation predicts overall survival, immune cell infiltration and response to immunotherapy in clear cell renal cell carcinoma., PMID:40448175
Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9., PMID:40445384
Correlation of serum Helios, CD226, TIGIT, and Foxp3 with tear film osmotic pressure and dry eye disease in patients with rheumatoid arthritis., PMID:40442984
Investigating the molecular mechanisms associated with ulcerative colitis through the application of single-cell combined spatial transcriptome sequencing., PMID:40433374
Investigation of TIGIT, PVRIG, CD112 and CD155 expression in early and late onset preeclampsia., PMID:40425968
Desmocollin-3 and Bladder Cancer., PMID:40422563
Distinct immunity dynamics of natural killer cells in mild and moderate COVID-19 cases during the Omicron variant phase., PMID:40421029
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy., PMID:40415479
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
Altered CD27-related T cell subsets reflect immune imbalance in systemic lupus erythematosus., PMID:40381105
TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis., PMID:40374622
ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer., PMID:40371640
Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients., PMID:40367012
New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer., PMID:40362333
TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model., PMID:40360046
Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies., PMID:40358739
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families., PMID:40356928
PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer., PMID:40344511
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer., PMID:40327600
Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma., PMID:40326845
GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout., PMID:40317320
Tph cells are expanded in IgA vasculitis nephritis., PMID:40315784
Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia., PMID:40313965
Immuno-PET Imaging of a 68Ga-Labeled Single-Domain Antibody for Detecting Tumor TIGIT Expression., PMID:40298304
T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy., PMID:40294684
An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer., PMID:40289088
SLAM receptors regulate immune checkpoints via SAP and EAT- 2 in rheumatoid arthritis: association with disease activity., PMID:40287562
UBASH3A and TIGIT genes expression levels in systemic sclerosis., PMID:40285746
LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy., PMID:40277786
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells., PMID:40274631
Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy., PMID:40261799
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications., PMID:40243372
Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity., PMID:40238864
Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML., PMID:40236710
CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma., PMID:40234092
Anti-TIGIT inhibitors plus PD-1 or PD-L1 inhibitors versus PD-1 or PD-L1 inhibitors for first-line treatment of advanced non-small cell lung cancer., PMID:40226904
Memory-promoting function of miR-379-5p attenuates CD8+ T cell exhaustion by targeting immune checkpoints., PMID:40221151
Single cell transcriptome sequencing indicates the cellular heterogeneity of small intestine tissue in celiac disease., PMID:40216823
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis., PMID:40214805
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505
For research use only. Not for human or drug use.
